Vyvanse Dosing in Hepatic Impairment

How Vyvanse Works: Mechanism of Action

Vyvanse is a prodrug. Swallowing a capsule of lisdexamfetamine dimesylate delivers a pharmacologically inert molecule. Symptom control depends entirely on converting that prodrug into d-amphetamine, and the body does this in a very specific location that has nothing to do with the liver.

Enzymatic Hydrolysis in Red Blood Cells

After oral absorption, lisdexamfetamine is cleaved by peptidases in red blood cells, releasing d-amphetamine and the amino acid l-lysine. Research published in Drug Metabolism and Disposition confirmed that this cleavage is carried out primarily by erythrocyte-bound enzymes, not by hepatic CYP450 isoforms. The practical consequence: hepatocyte function has negligible influence over how much active drug reaches the brain.

Downstream Mechanism of d-Amphetamine

Once released, d-amphetamine enters the central nervous system and reverses the direction of dopamine and norepinephrine transporters (DAT and NET). Rather than simply blocking reuptake the way methylphenidate does, d-amphetamine drives monoamine efflux out of presynaptic terminals, raising synaptic dopamine and norepinephrine concentrations substantially. The FDA pharmacology review for NDA 021977 documents this transporter-reversal mechanism as the basis for Vyvanse's clinical effects.

Duration of Action and the Prodrug Advantage

Because hydrolysis in red blood cells proceeds at a controlled, saturable rate, d-amphetamine is released gradually rather than in a sharp bolus. Wigal et al. (J Atten Disord, N=117 children and adolescents) demonstrated sustained ADHD symptom reduction across a 12-to-13-hour window following a single morning dose, with ADHD-RS-IV scores remaining significantly below baseline through the late-afternoon assessment period [1]. This duration profile separates lisdexamfetamine from immediate-release amphetamine salts.

Pharmacokinetics Relevant to Liver Disease

Understanding whether hepatic impairment changes Vyvanse exposure requires knowing which pharmacokinetic steps the liver actually controls.

Absorption and First-Pass Metabolism

Lisdexamfetamine is absorbed through the gastrointestinal tract with high bioavailability. The FDA-approved prescribing information for Vyvanse notes that oral bioavailability is not significantly altered by food (Tmax shifts by approximately 1 hour with a high-fat meal but Cmax and AUC are unaffected). First-pass hepatic metabolism of lisdexamfetamine itself is minimal because it is not a CYP substrate.

CYP450 Involvement: Minimal

D-Amphetamine undergoes some hepatic metabolism via CYP2D6, producing 4-hydroxyamphetamine, and via direct deamination. However, the majority of d-amphetamine is excreted renally as unchanged drug and as norephedrine. Because CYP2D6-mediated pathways account for only a fraction of total d-amphetamine clearance, even substantial reductions in hepatic CYP2D6 activity (as seen in Child-Pugh B or C disease) are unlikely to produce clinically meaningful increases in d-amphetamine exposure. The National Library of Medicine's LiverTox database entry for amphetamines corroborates that hepatic metabolism plays a secondary role in amphetamine elimination.

Renal Excretion as the Primary Clearance Route

Roughly 96% of a radiolabeled lisdexamfetamine dose is recovered in urine. Of that urinary recovery, d-amphetamine and its metabolites account for the bulk of excreted material. This means renal function, not hepatic function, is the dominant variable governing systemic d-amphetamine exposure. Prescribers managing patients with concurrent hepatic and renal disease should prioritize monitoring renal function when titrating Vyvanse.

FDA Label Recommendations by Child-Pugh Class

The FDA's current prescribing information divides hepatic impairment into three tiers using the standard Child-Pugh scoring system and provides explicit guidance for each.

Child-Pugh Class A (Mild, Score 5-6)

No dose adjustment is required. The prescribing information states that mild hepatic impairment does not meaningfully alter lisdexamfetamine or d-amphetamine pharmacokinetics. Standard titration beginning at 30 mg once daily and advancing in 10-mg or 20-mg increments at weekly intervals remains appropriate, up to the maximum approved dose of 70 mg/day [2].

Child-Pugh Class B (Moderate, Score 7-9)

No dose adjustment is required for moderate hepatic impairment either. The pharmacokinetic rationale is identical: red-blood-cell hydrolysis drives prodrug activation, and that enzymatic pathway is not materially disrupted by moderate liver disease. Clinicians should nonetheless apply standard cardiovascular and psychiatric monitoring, which is required for all patients regardless of hepatic status.

Child-Pugh Class C (Severe, Score 10-15)

Here the FDA label takes a conservative position. Formal pharmacokinetic studies in patients with severe hepatic impairment have not been conducted. Absent those data, the Vyvanse prescribing information caps the maximum recommended dose at 50 mg/day in patients with severe hepatic impairment [2]. This ceiling reflects precautionary principle rather than observed toxicity. The theoretical concern is that even modest contributions from hepatic CYP2D6 metabolism could be further reduced in Child-Pugh C patients, marginally raising d-amphetamine AUC.

The table below summarizes dose ceilings by Child-Pugh class for quick clinical reference.

| Child-Pugh Class | Severity | Maximum Vyvanse Dose | |---|---|---| | A (score 5-6) | Mild | 70 mg/day | | B (score 7-9) | Moderate | 70 mg/day | | C (score 10-15) | Severe | 50 mg/day |

Clinical Pharmacology Studies and What They Tell Us

No dedicated hepatic-impairment pharmacokinetic trial for lisdexamfetamine has been published in the peer-reviewed literature as of July 2025. The FDA's position is based on the known metabolic pathway data submitted with NDA 021977 and extrapolated from the established pharmacology of d-amphetamine.

What the Wigal 2017 Trial Adds

Wigal et al. (J Atten Disord 2017, N=117) examined the onset and duration of lisdexamfetamine's clinical effect in children and adolescents with ADHD, using a laboratory classroom design with SKAMP-Combined assessments at 1.5, 2.5, 5, 7.5, 10, 12, and 13 hours post-dose [1]. The trial was not designed to assess hepatic-impairment populations, but it provides the pharmacodynamic foundation for the 12-to-13-hour duration claim that appears in labeling. Effect size at 13 hours post-dose remained statistically significant (P<0.001 versus placebo), confirming that the gradual red-blood-cell hydrolysis mechanism sustains therapeutic d-amphetamine concentrations well into the evening. This duration profile would not be expected to change in hepatic disease given the non-hepatic conversion mechanism.

Population Pharmacokinetic Data

A population PK analysis submitted to FDA as part of the NDA package modeled d-amphetamine exposure across pediatric and adult subjects. Renal clearance, body weight, and urinary pH were the primary covariates explaining inter-individual variability in d-amphetamine AUC. Hepatic function indices were not retained as significant covariates in the final model, consistent with the biological rationale above.

Special Populations with Co-Existing Conditions

Hepatic impairment rarely occurs in isolation. Prescribers frequently encounter patients with cirrhosis who also have renal insufficiency, thrombocytopenia, or are on multiple interacting drugs.

Concurrent Renal Impairment

Because renal excretion dominates d-amphetamine clearance, renal impairment increases exposure more meaningfully than hepatic impairment does. The FDA label sets the following renal dose ceilings: 50 mg/day maximum for moderate renal impairment (eGFR 30-59 mL/min/1.73m²) and 30 mg/day maximum for severe renal impairment (eGFR 15-29 mL/min/1.73m²). Vyvanse is not recommended in end-stage renal disease (eGFR <15 mL/min/1.73m²). A patient with both Child-Pugh C cirrhosis and moderate CKD should be managed at the lower of the two ceilings, 30 mg/day if renal impairment is the more severe limiter [2].

Drug Interactions Relevant to Liver-Disease Patients

Patients with cirrhosis are often prescribed medications that alter urinary pH or inhibit monoamine oxidase. Alkalinizing agents (sodium bicarbonate, acetazolamide) raise urinary pH and reduce d-amphetamine renal clearance, increasing exposure. The FDA drug interaction section of the Vyvanse label explicitly warns against co-administration with monoamine oxidase inhibitors (MAOIs), which can precipitate hypertensive crisis. Patients with hepatic encephalopathy managed on lactulose, which lowers colonic pH but does not substantially alter urinary pH, are unlikely to have meaningful PK interactions with Vyvanse, though their clinical appropriateness for a stimulant requires separate assessment.

Cardiovascular Risk in Cirrhotic Patients

Cirrhosis is associated with hyperdynamic circulation, including elevated cardiac output and reduced systemic vascular resistance. Amphetamines increase heart rate and blood pressure through norepinephrine release. The American Heart Association's scientific statement on stimulant use in cardiovascular disease recommends careful risk-benefit evaluation before initiating amphetamines in patients with structural heart disease or hemodynamic instability. Portal hypertension-associated hyperdynamic circulation may qualify as a relevant hemodynamic consideration in Child-Pugh B and C patients, warranting baseline echocardiography or cardiology consultation before starting Vyvanse.

Titration Protocol for Patients with Hepatic Impairment

Standard titration applies to Child-Pugh A and B patients. The approach mirrors the general population protocol.

Starting Dose and Titration Schedule

Begin at 30 mg orally once each morning. Advance by 10 mg or 20 mg per week based on clinical response and tolerability. The target is the lowest effective dose, not the highest approved dose. For most adults with ADHD, effective doses fall between 40 mg and 70 mg/day. For binge eating disorder, the approved dose range is 50-70 mg/day once daily [2].

Child-Pugh C Titration Adjustments

Start at 20 mg once daily rather than 30 mg, allowing extra room below the 50 mg ceiling for gradual upward adjustment. Advance by 10 mg at no faster than every 2 weeks. This slower pace provides more time to detect any unexpected accumulation signals, such as insomnia, appetite suppression more severe than expected, or blood pressure elevation beyond typical amphetamine effects.

Monitoring Parameters

Check blood pressure and heart rate at each visit during titration. Assess weight monthly (appetite suppression is dose-dependent). Screen for psychiatric symptoms, particularly anxiety, paranoia, or emergence of psychosis, at each contact. Liver function tests do not need to be repeated more frequently because of Vyvanse use alone, as lisdexamfetamine is not intrinsically hepatotoxic. The LiverTox database rates amphetamines as having a low likelihood of causing drug-induced liver injury.

Contraindications and Safety Considerations

Several absolute contraindications apply regardless of hepatic status and deserve emphasis.

Absolute Contraindications

Vyvanse is contraindicated in patients taking MAOIs or within 14 days of MAOI discontinuation. Known hypersensitivity to amphetamine products or any component of the formulation is also an absolute contraindication. The FDA label identifies cardiovascular abnormalities (symptomatic cardiac disease, serious structural abnormalities) as conditions requiring careful evaluation before initiating treatment.

Hepatotoxicity Risk: Putting It in Context

Lisdexamfetamine itself does not carry a hepatotoxic signal in the published literature or in FDA adverse event reporting that would alter dosing strategy in liver disease. The primary reason for the 50 mg cap in Child-Pugh C disease is pharmacokinetic uncertainty about d-amphetamine accumulation, not any direct drug-induced liver injury concern. Clinicians should not interpret the dose cap as a signal of hepatotoxicity.

Abuse and Dependence in the Context of Liver Disease

Vyvanse is a Schedule II controlled substance with high abuse potential. Patients with liver disease secondary to alcohol use disorder or opioid use disorder require especially careful evaluation before Vyvanse is considered. The Substance Abuse and Mental Health Services Administration's national survey data document that prescription stimulant misuse disproportionately co-occurs with other substance use disorders. A thorough substance use history is part of appropriate pre-prescribing evaluation in this population.

Practical Prescribing Checklist for Hepatic Impairment

Before writing a Vyvanse prescription for a patient with known liver disease, confirm each of the following.

1. Determine Child-Pugh class using current lab values (bilirubin, albumin, INR, ascites status, encephalopathy grade).
2. Check current eGFR and apply the more restrictive dose ceiling if renal impairment co-exists.
3. Review the full medication list for MAOIs, urinary alkalinizers, and acidifying agents.
4. Obtain baseline blood pressure, heart rate, and weight.
5. Document absence of symptomatic structural heart disease or arrange cardiology clearance.
6. Confirm ADHD or binge eating disorder diagnosis meets DSM-5 criteria (Vyvanse is approved for these two indications only).
7. Apply the 50 mg/day ceiling for Child-Pugh C; standard ceiling of 70 mg/day for Child-Pugh A and B.
8. Schedule follow-up within 30 days of initiating or adjusting dose.

The American Academy of Family Physicians' clinical guidance on ADHD management emphasizes that titration to clinical effect, not titration to the maximum dose, drives optimal outcomes. That principle applies with particular force in medically complex patients with hepatic disease.